Clinical Trials Logo
  1. Home
  2. Mammographic Density
  3. NCT03629717

RANKL Inhibition and Breast Tissue Biomarkers

Mammographic Density Clinical Trial

Official title:
RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts

Clinical Trial Summary

A robust knowledge of how to reduce breast density could play a key role in breast cancer prevention in premenopausal women, but viable preventative targets to reduce breast density-associated breast cancer risk are yet to be developed. The investigators propose to investigate the effect of RANKL inhibition with denosumab on breast tissue markers in high-risk premenopausal women with dense breasts. Study findings could provide robust evidence to move forward with a clinical trial targeting RANKL inhibition in premenopausal breast cancer prevention.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03629717
Study type Interventional
Source Washington University School of Medicine
Contact
Status Completed
Phase Early Phase 1
Start date June 1, 2018
Completion date December 3, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02524561 - KEEPS Mammographic Density And Breast Health Ancillary Study N/A
Enrolling by invitation NCT03686098 - The Malaysian Soy and Mammographic Density Study N/A
Completed NCT04096469 - Impact of Diet and Physical Activity Changes on Body Weight, Biomarkers and Quality of Life in Breast Cancer Survivors N/A
Completed NCT04079517 - Karolinska Interventional Study of Mammograhic Density (Karisma-1) Phase 1/Phase 2
Completed NCT03264651 - Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density Phase 1
Not yet recruiting NCT03696147 - Diffusion Magnetic Resonance Imaging in Mamographically Detected Asymmetric Densities
Completed NCT03314298 - A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole Phase 1